Fundraising FoxSolace Therapeutics
Framingham, US · Delaware corporation · 1 known investors
Find your way into Solace Therapeutics
Sign up to see every warm intro you have to Solace Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Solace Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
WH
William H. GruberExecutive
Board
RD
Ryan DrantBoard directorGeneral Partner at New Enterprise Associates (NEA)
JD
J. Daniel ColeBoard director
JM
John McDonoughBoard director
SE
Stacy Enxing SengBoard director
KG
Kevin G. ConnorsBoard director
DW
Dr. William PintauroBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$28.4M disclosed across 4 rounds · 2012–2020
▶$6.5MraisedFeb 2021 · 8 investors · Other Health CareRule 506(b)
▶$6.5MraisedFeb 2021 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- William H. GruberExecutive Officer, Director
- Kevin G. ConnorsDirector
- Brian R. SmithDirector
- John McDonoughDirector
- David NeustaedterDirector
- Offering amount
- $17.6M
- Amount sold
- $6.5M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedFeb 2019 · 6 investors · Other Health CareRule 506(b)
▶$1.9MraisedFeb 2019 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kevin G. ConnorsExecutive Officer, Director
- John McDonoughDirector
- Ryan DrantDirector
- Ali BehbahaniDirector
- William H. GruberExecutive Officer, Director
- Stacy Enxing SengDirector
- Offering amount
- $2.1M
- Amount sold
- $1.9M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13MraisedSep 2016 · 2 investors · Other Health CareRule 506(b)
▶$13MraisedSep 2016 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John McDonoughDirector
- Stacy Enxing SengDirector
- Kevin G. ConnorsDirector
- William H. GruberExecutive Officer, Director
- Ali BehbahaniDirector
- Ryan DrantDirector
- Offering amount
- $20M
- Amount sold
- $13M
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedMar 2012 · Other Health CareRule 506(b)
▶$7MraisedMar 2012 · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kevin ConnorsExecutive Officer, Director
- Dr. William PintauroDirector
- J. Daniel ColeDirector
- William H. GruberExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $7M
- First sale
- Mar 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Solace Therapeutics's investors?
- Solace Therapeutics's investors include New Enterprise Associates (NEA).
- How much funding has Solace Therapeutics raised?
- Solace Therapeutics has disclosed $28.4M raised across 4 rounds.
- Where is Solace Therapeutics headquartered?
- Solace Therapeutics is headquartered in Framingham, US.